# A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency

> **NCT03378531** · PHASE2 · COMPLETED · sponsor: **Aeglea Biotherapeutics** · enrollment: 14 (actual)

## Conditions studied

- Arginase I Deficiency
- Hyperargininemia

## Interventions

- **DRUG:** AEB1102

## Key facts

- **NCT ID:** NCT03378531
- **Lead sponsor:** Aeglea Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-07
- **Primary completion:** 2022-12-15
- **Final completion:** 2022-12-15
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2023-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03378531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03378531, "A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03378531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*